Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]